论文部分内容阅读
目的通过使用比索洛尔和(或)氯沙坦钾对舒张性心力衰竭(DHF)进行治疗,观察其脑钠肽(BNP)及脉搏波传导速度(PWV)的变化。方法以2013年10月1日—2014年12月31日郑州人民医院心内科入院DHF患者150例为研究对象,随机分为比索洛尔治疗组(A组)50例,氯沙坦钾治疗组(B组)50例,比索洛尔联合氯沙坦钾治疗组(C组)50例,3组均给予常规对症处理,入院时分别检测PWV,心脏彩超(LVEF,E/A),脑钠肽(BNP)。服药半年后复测上述指标。结果治疗前三组间PWV,LVEF,E/A,BNP均无统计学差异(P>0.05),治疗后三组间PWV,BNP、E/A均明显改变(P<0.05),且C组改善更为明显,LVEF无明显差异(P>0.05)。结论在常规治疗基础上给予比索洛尔或氯沙坦钾可显著改善DHF患者心功能及动脉硬化,联合使用会取得更显著的变化。
Objective To observe the changes of brain natriuretic peptide (BNP) and pulse wave velocity (PWV) in patients with diastolic heart failure (DHF) by using bisoprolol and / or losartan potassium. Methods 150 patients admitted to Department of Cardiology, Zhengzhou People’s Hospital from October 1, 2013 to December 31, 2014 were randomly divided into two groups: 50 patients in the bisoprolol group (group A), 50 patients in the losartan potassium group (Group B) 50 cases, bisoprolol plus losartan potassium group (group C) 50 cases, 3 groups were given conventional symptomatic treatment, were admitted to PWV, LVEF (E / A), brain natriuretic peptide Peptide (BNP). Retest the above indicators six months after taking the drug. Results There were no significant differences in PWV, LVEF, E / A and BNP between the three groups before treatment (P> 0.05). PWV, BNP and E / A in the three groups were significantly changed after treatment The improvement was more obvious, LVEF no significant difference (P> 0.05). Conclusions The administration of bisoprolol or losartan on the basis of conventional therapy can significantly improve the cardiac function and arteriosclerosis in DHF patients, and the more significant changes will be achieved when used in combination.